Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial

[1]  F. Vicini,et al.  NRG RTOG 1005: A Phase III Trial of Hypo Fractionated Whole Breast Irradiation with Concurrent Boost vs. Conventional Whole Breast Irradiation Plus Sequential Boost Following Lumpectomy for High Risk Early-Stage Breast Cancer , 2022, International Journal of Radiation Oncology*Biology*Physics.

[2]  J. Overgaard,et al.  OC-0102 DBCG phase III randomized trial of hypo- vs standard fractionated RT in 2879 pN+ breast cancer pts , 2022, Radiotherapy and Oncology.

[3]  L. Boersma,et al.  European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. , 2022, The Lancet. Oncology.

[4]  M. D. De Santis,et al.  Review of: "Acute toxicity and health-related quality of life after accelerated whole breast irradiation in 5 fractions with simultaneous integrated boost" , 2021 .

[5]  C. Coles,et al.  Moving Forward Fast with FAST-Forward. , 2021, Clinical oncology (Royal College of Radiologists (Great Britain)).

[6]  M. Mareel,et al.  Acute toxicity and health-related quality of life after accelerated whole breast irradiation in 5 fractions with simultaneous integrated boost , 2020, Breast.

[7]  R. Ahmed,et al.  Hypofractionated radiation therapy comparing a standard radiotherapy schedule (over 3 weeks) with a novel 1-week schedule in adjuvant breast cancer: an open-label randomized controlled study (HYPORT-Adjuvant)—study protocol for a multicentre, randomized phase III trial , 2020, Trials.

[8]  E. Sawyer,et al.  Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial , 2020, The Lancet.

[9]  H. Bartelink,et al.  Predictors for poor cosmetic outcome in patients with early stage breast cancer treated with breast conserving therapy: Results of the Young boost trial. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[10]  I. Ellis,et al.  Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial , 2017, The Lancet.

[11]  E. van Limbergen,et al.  Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial , 2017, JAMA oncology.

[12]  J. Yarnold,et al.  Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  Laurence Collette,et al.  Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer. , 2015, The New England journal of medicine.

[14]  E. van Limbergen,et al.  Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. , 2015, The Lancet. Oncology.

[15]  T. Whelan,et al.  Regional Nodal Irradiation in Early-Stage Breast Cancer. , 2015, The New England journal of medicine.

[16]  H. Bartelink,et al.  A multicentre observational study evaluating image-guided radiotherapy for more accurate partial-breast intensity-modulated radiotherapy: comparison with standard imaging technique , 2014 .

[17]  R. Mansel,et al.  Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. , 2014, The Lancet. Oncology.

[18]  C. Coles,et al.  The Cambridge Breast Intensity-modulated Radiotherapy Trial: patient- and treatment-related factors that influence late toxicity. , 2011, Clinical oncology (Royal College of Radiologists (Great Britain)).

[19]  Sarah L Vowler,et al.  Evaluation of implanted gold seeds for breast radiotherapy planning and on treatment verification: a feasibility study on behalf of the IMPORT trialists. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[20]  J. Yarnold,et al.  Planning with intensity-modulated radiotherapy and tomotherapy to modulate dose across breast to reflect recurrence risk (IMPORT High trial). , 2011, International journal of radiation oncology, biology, physics.

[21]  E. van Limbergen,et al.  Impact of the boost dose of 10 Gy versus 26 Gy in patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10-year results of the randomised EORTC boost trial. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[22]  Michel Bolla,et al.  Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882 'boost versus no boost'. , 2008, European journal of cancer.

[23]  D. Tait,et al.  Evaluation of a method for grading late photographic change in breast appearance after radiotherapy for early breast cancer. , 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).

[24]  J. Yarnold,et al.  The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial , 2008, The Lancet. Oncology.

[25]  J R Yarnold,et al.  The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial , 2008, The Lancet.

[26]  A. Dhar,et al.  National Institute for Health and Clinical Excellence , 2005 .

[27]  U. Veronesi,et al.  Reoperation for locally recurrent breast cancer in patients previously treated with conservative surgery , 1999, The British journal of surgery.

[28]  P. Romestaing,et al.  Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  H. Welch,et al.  Using Autopsy Series To Estimate the Disease Reservoir for Ductal Carcinoma in Situ of the Breast: How Much More Breast Cancer Can We Find? , 1997, Annals of Internal Medicine.

[30]  A. Hart,et al.  Dose and volume effects on fibrosis after breast conservation therapy. , 1994, International journal of radiation oncology, biology, physics.